179 related articles for article (PubMed ID: 36140756)
1. Evolutionary Trajectories of Primary and Metastatic Pancreatic Neuroendocrine Tumors Based on Genomic Variations.
Xu M; Yan J; Hu B; Wu C; Gu H; Qi Z; Chen T; Yang W; Zheng Y; Dong H; Sheng W; Long J
Genes (Basel); 2022 Sep; 13(9):. PubMed ID: 36140756
[TBL] [Abstract][Full Text] [Related]
2. Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases.
Pea A; Yu J; Marchionni L; Noe M; Luchini C; Pulvirenti A; de Wilde RF; Brosens LA; Rezaee N; Javed A; Chianchiano P; Gobbo S; Regi P; Salvia R; Bassi C; He J; Weiss MJ; Cameron JL; Offerhaus GJA; Hruban RH; Lawlor RT; Scarpa A; Heaphy CM; Wood LD; Wolfgang CL
Ann Surg; 2020 Mar; 271(3):566-573. PubMed ID: 30339629
[TBL] [Abstract][Full Text] [Related]
3. Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns.
Jiang Y; Dong YH; Zhao SW; Liu DY; Zhang JY; Xu XY; Chen H; Chen H; Jin JB
Cell Commun Signal; 2024 Mar; 22(1):164. PubMed ID: 38448900
[TBL] [Abstract][Full Text] [Related]
4. Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times.
Roy S; LaFramboise WA; Liu TC; Cao D; Luvison A; Miller C; Lyons MA; O'Sullivan RJ; Zureikat AH; Hogg ME; Tsung A; Lee KK; Bahary N; Brand RE; Chennat JS; Fasanella KE; McGrath K; Nikiforova MN; Papachristou GI; Slivka A; Zeh HJ; Singhi AD
Gastroenterology; 2018 Jun; 154(8):2060-2063.e8. PubMed ID: 29486199
[TBL] [Abstract][Full Text] [Related]
5. Molecular and Functional Heterogeneity of Primary Pancreatic Neuroendocrine Tumors and Metastases.
Guo Y; Tian C; Cheng Z; Chen R; Li Y; Su F; Shi Y; Tan H
Neuroendocrinology; 2023; 113(9):943-956. PubMed ID: 37232011
[TBL] [Abstract][Full Text] [Related]
6. Genomic landscape of pancreatic neuroendocrine tumors.
Gebauer N; Schmidt-Werthern C; Bernard V; Feller AC; Keck T; Begum N; Rades D; Lehnert H; Brabant G; Thorns C
World J Gastroenterol; 2014 Dec; 20(46):17498-506. PubMed ID: 25516664
[TBL] [Abstract][Full Text] [Related]
7. Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor.
Williamson LM; Steel M; Grewal JK; Thibodeau ML; Zhao EY; Loree JM; Yang KC; Gorski SM; Mungall AJ; Mungall KL; Moore RA; Marra MA; Laskin J; Renouf DJ; Schaeffer DF; Jones SJM
Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160355
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of aberrant DNA methylation in g1 and g2 pancreatic neuroendocrine tumors.
Stefanoli M; La Rosa S; Sahnane N; Romualdi C; Pastorino R; Marando A; Capella C; Sessa F; Furlan D
Neuroendocrinology; 2014; 100(1):26-34. PubMed ID: 25011998
[TBL] [Abstract][Full Text] [Related]
9. Angiopoietin-2 blockade suppresses growth of liver metastases from pancreatic neuroendocrine tumors by promoting T cell recruitment.
Lee E; O'Keefe S; Leong A; Park HR; Varadarajan J; Chowdhury S; Hiner S; Kim S; Shiva A; Friedman RA; Remotti H; Fojo T; Yang HW; Thurston G; Kim M
J Clin Invest; 2023 Oct; 133(20):. PubMed ID: 37843277
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for short recurrence-free survival after resection of pancreatic neuroendocrine tumor (PanNET) liver metastases: which patients should undergo resection?
Masui T; Nagai K; Anazawa T; Kasai Y; Sato A; Nakano K; Uchida Y; Yogo A; Kawaguchi Y; Takaori K; Uemoto S
Scand J Gastroenterol; 2020 Apr; 55(4):479-484. PubMed ID: 32223573
[No Abstract] [Full Text] [Related]
11. Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression.
Martin DR; LaBauve E; Pomo JM; Chiu VK; Hanson JA; Gullapalli RR
Pancreas; 2018 Apr; 47(4):502-510. PubMed ID: 29521944
[TBL] [Abstract][Full Text] [Related]
12. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM
Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587
[No Abstract] [Full Text] [Related]
13. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.
Hackeng WM; Brosens LAA; Kim JY; O'Sullivan R; Sung YN; Liu TC; Cao D; Heayn M; Brosnan-Cashman J; An S; Morsink FHM; Heidsma CM; Valk GD; Vriens MR; Nieveen van Dijkum E; Offerhaus GJA; Dreijerink KMA; Zeh H; Zureikat AH; Hogg M; Lee K; Geller D; Marsh JW; Paniccia A; Ongchin M; Pingpank JF; Bahary N; Aijazi M; Brand R; Chennat J; Das R; Fasanella KE; Khalid A; McGrath K; Sarkaria S; Singh H; Slivka A; Nalesnik M; Han X; Nikiforova MN; Lawlor RT; Mafficini A; Rusev B; Corbo V; Luchini C; Bersani S; Pea A; Cingarlini S; Landoni L; Salvia R; Milione M; Milella M; Scarpa A; Hong SM; Heaphy CM; Singhi AD
Gut; 2022 May; 71(5):961-973. PubMed ID: 33849943
[TBL] [Abstract][Full Text] [Related]
14. Surgery for metastatic pancreatic neuroendocrine tumors: a narrative review.
Williams JK; Schwarz JL; Keutgen XM
Hepatobiliary Surg Nutr; 2023 Feb; 12(1):69-83. PubMed ID: 36860243
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of Altered ATRX/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis.
Wang F; Xu X; Ye Z; Qin Y; Yu X; Ji S
Front Endocrinol (Lausanne); 2021; 12():691557. PubMed ID: 34220718
[TBL] [Abstract][Full Text] [Related]
16. Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors.
Krauss T; Ferrara AM; Links TP; Wellner U; Bancos I; Kvachenyuk A; Villar Gómez de Las Heras K; Yukina MY; Petrov R; Bullivant G; von Duecker L; Jadhav S; Ploeckinger U; Welin S; Schalin-Jäntti C; Gimm O; Pfeifer M; Ngeow J; Hasse-Lazar K; Sansó G; Qi X; Ugurlu MU; Diaz RE; Wohllk N; Peczkowska M; Aberle J; Lourenço DM; Pereira MAA; Fragoso MCBV; Hoff AO; Almeida MQ; Violante AHD; Quidute ARP; Zhang Z; Recasens M; Díaz LR; Kunavisarut T; Wannachalee T; Sirinvaravong S; Jonasch E; Grozinsky-Glasberg S; Fraenkel M; Beltsevich D; Egorov VI; Bausch D; Schott M; Tiling N; Pennelli G; Zschiedrich S; Därr R; Ruf J; Denecke T; Link KH; Zovato S; von Dobschuetz E; Yaremchuk S; Amthauer H; Makay Ö; Patocs A; Walz MK; Huber TB; Seufert J; Hellman P; Kim RH; Kuchinskaya E; Schiavi F; Malinoc A; Reisch N; Jarzab B; Barontini M; Januszewicz A; Shah N; Young WF; Opocher G; Eng C; Neumann HPH; Bausch B
Endocr Relat Cancer; 2018 Sep; 25(9):783-793. PubMed ID: 29748190
[TBL] [Abstract][Full Text] [Related]
17. High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor.
Lee YS; Kim H; Kim HW; Lee JC; Paik KH; Kang J; Kim J; Yoon YS; Han HS; Sohn I; Cho J; Hwang JH
Medicine (Baltimore); 2015 Dec; 94(50):e2224. PubMed ID: 26683934
[TBL] [Abstract][Full Text] [Related]
18. DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors.
Cives M; Partelli S; Palmirotta R; Lovero D; Mandriani B; Quaresmini D; Pelle' E; Andreasi V; Castelli P; Strosberg J; Zamboni G; Falconi M; Silvestris F
Sci Rep; 2019 Dec; 9(1):18614. PubMed ID: 31819132
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic Neuroendocrine Tumors.
Salaria SN; Shi C
Surg Pathol Clin; 2016 Dec; 9(4):595-617. PubMed ID: 27926362
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic neuroendocrine tumors with somatostatin expression and paraganglioma-like features.
Konukiewitz B; von Hornstein M; Jesinghaus M; Steiger K; Weichert W; Detlefsen S; Kasajima A; Klöppel G
Hum Pathol; 2020 Aug; 102():79-87. PubMed ID: 32668277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
